Evidence map›Paper›PMID 42146710›Full record

ArticlebioRxiv : the preprint server for biology2026

Modeling human B cell development with pluripotent stem cells.

Xiaoning Sun, Jamie J Kwan, Krishna Kothari, Alexandra F Nazzari, Astrid Kosters, Colin A Fields, Bao Q Thai, Deepta Bhattacharya, Michael Atkins, Kelvin Chan Tung and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaoning SunMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Jamie J KwanMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Krishna KothariDepartments of Medicine and Pediatrics, Division of Immunology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.
Alexandra F NazzariDepartments of Medicine and Pediatrics, Division of Immunology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.
Astrid KostersDepartments of Medicine and Pediatrics, Division of Immunology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.
Colin A FieldsDepartment of Immunobiology, University of Arizona College of Medicine, Tucson AZ 85724.
Bao Q ThaiDepartment of Immunobiology, University of Arizona College of Medicine, Tucson AZ 85724.
Deepta BhattacharyaDepartment of Immunobiology, University of Arizona College of Medicine, Tucson AZ 85724.
Michael AtkinsMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Kelvin Chan TungMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Xinyuan ZhaoMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Vladimir T ManchevMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Marion KennedyMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.
Eliver GhosnDepartments of Medicine and Pediatrics, Division of Immunology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.ORCID 0000-0001-7258-906X
Gordon KellerMcEwen Stem Cell Institute, University Health Network, Toronto, ON M5G1L7, Canada.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
TRANSCRIPTIONAL REGULATION OF ANTIBODY RESPONSES AND IMMUNITYR01AI099108 · NIAID · WASHINGTON UNIVERSITY · PI Deepta Bhattacharya · 2012 to 2026
$6.4M
Early Life B-cell and plasma cell development in the human Spleen: a new paradigm for lifelong immunityR01AI182276 · NIAID · EMORY UNIVERSITY · PI Eliver Ghosn · 2025 to 2026
$1.6M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
Bill & Melinda Gates Foundation INV-007910Bill & Melinda Gates Foundation INV-044064NCI NIH HHS P30 CA023074NIAID NIH HHS R01 AI099108NIAID NIH HHS R01 AI182276NIH HHS P51 OD011132NIH HHS S10 OD026799
6 · The paper itself

Abstract

The ability to generate functional B cells from human pluripotent stem cells (hPSCs) would open new opportunities to develop novel B cell-based therapies to treat a range of human diseases and disorders. Towards this goal, we established a protocol that promotes the efficient development of B lineage cells from definitive hematopoietic progenitors generated from different hPSC lines. Flow cytometric and multi-omic scRNA-seq analyses revealed that B cell development from hPSCs transitions through the well-established pro-B, pre-B and naïve B cell stages, accurately recapitulating B lymphopoiesis in the human adult bone marrow. Importantly, the naïve B cells generated with this approach could be induced to mature into plasma cells that secrete antibodies and undergo class switching. Analyses of signaling pathways that regulate B lymphopoiesis in these cultures uncovered a potent inhibitory effect of IL-7 on functional IgH rearrangement, resulting in the development of abnormal cells that failed to undergo pre-B cell maturation. Finally, analysis of the different hPSC-derived hematopoietic programs revealed that both definitive and yolk sac progenitors display B cell potential, indicating that there are distinct developmental sources of human B lineage cells. Taken together, these findings demonstrate the efficient generation of B cells from hPSCs and, in doing so, provide a system for further investigating the earliest stages of human B lymphopoiesis and a source of appropriately staged plasma cells for future therapeutic applications.

Identifiers

PMID42146710
PMCPMC13174478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.